Ironwood Pharmaceuticals (IRWD) Total Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals has reported Total Non-Current Liabilities for 15 years, with the latest figure at $413.4 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 33.39% year-over-year to $413.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $413.4 million (up 33.39% YoY) and the FY2025 annual result came in at $375.3 million, up 12.42% from the prior year.
• Total Non-Current Liabilities improved to $413.4 million in Q1 2026 per IRWD's latest filing, from $375.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1.1 billion in Q1 2023 and troughed at $309.9 million in Q1 2025.
• A 5-year average of $592.2 million and a median of $413.4 million in 2026 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 80.4% in 2022, then tumbled 64.2% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $1.1 billion in 2022, then plunged by 59.42% to $442.7 million in 2023, then decreased by 24.59% to $333.8 million in 2024, then increased by 12.42% to $375.3 million in 2025, then increased by 10.16% to $413.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $413.4 million, $375.3 million, and $373.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.